Vinod Khosla's Menlo Park venture firm, which backs bold early-stage technology companies including health and biology start-ups. Cancer-related bets include the blood-test company Guardant Health and the AI oncology start-up Radical Health.
Khosla Ventures was founded in 2004 by Vinod Khosla, a former Kleiner Perkins general partner, and is based in Menlo Park (Wikipedia). It invests from seed through growth with a 'venture assistance' model and is known for early conviction in categories 'before they had names', with OpenAI, DoorDash and Rocket Lab among its highlighted companies. Healthcare is one of several themes. Its portfolio page lists Guardant Health ('Transforming cancer care through blood tests', Nasdaq: GH), Radical Health ('AI-driven oncology platform turning subjective treatment decisions into scalable, data-driven precision care'), Rad AI (AI for medical imaging) and delivery companies with cancer milestones such as a macrophage-targeting lipid nanoparticle programme entering phase 1 in cancer in 2026.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| CHARM Therapeutics London, GB | Growth stage | biotech | Acute myeloid leukaemiaNPM1-mutated and KMT2A-rearranged acute myeloid leukaemia | Series B 2025, $80M |
| Liberate Bio Cambridge, MA, US | Startup | biotech | Seed 2025, $31M | |
| Noetik South San Francisco, CA, US | Startup | ai software | Series A 2024, $40M | |
| Radical Health San Francisco, CA, US | Startup | ai software | Pre-seed 2025, $5M | |
| Stylus Medicine Cambridge, MA, US | Startup | biotech | Series A 2025, $85M |
Shares CHARM Therapeutics and the tag vc.
Shares Noetik and the tag vc.
Shares CHARM Therapeutics and the tag vc.
Shares Noetik and the tag vc.
Shares Stylus Medicine and the tag vc.
Shares CHARM Therapeutics and the tag vc.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/